Allergy
Urticaria and Angioedema: The Role of Over-The-Counter Antihistamines
This program is designed to provide you with practical information to support treatment decisions for urticaria and angioedema in adults, with discussions around the safety profile of first- and second-generation OTC H1-antihistamines, as well as concerning clinical features of urticaria and angioedema that may prompt further evaluation and consultation.
DURATION
30 min
PROFESSION
Pharmacy
# OF CREDITS
1.0
ACCREDITATION
CCCEP
EXPIRY DATE
2024-05-11
Urticaria is a common and heterogeneous inflammatory skin disorder classified as either acute urticaria (≤ 6 weeks) or chronic urticaria (> 6 weeks). This program provides evidence-based guidance on the initial assessment and management of urticaria and angioedema, focusing on first-line treatment in adults with second-generation over-the-counter (OTC) H1-antihistamines.
This program has received an educational grant or in-kind support from Sanofi.
Faculty
Gordon Sussman, MD, FRCP( C ), FACP, DIP.ABIM, FAAAAI
Michael Boivin, RPh
Kelly Haggerty, RPh
Learning objectives
Upon completion of this continuing education, program participants will be better able to:
- Describe the clinical presentation and etiology of urticaria and angioedema
- Apply evidence-informed over-the-counter (OTC) treatment recommendations for urticaria and angioedema
- Recognize when additional consultation is required for urticaria and angioedema management
Accreditation
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.0 CEU(s).
CCCEP File Number: 1066-2023-3612-I-P